Skip Nav Destination
Close Modal
Search Results for
Food and Drug Administration
Update search
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
- Title
- Authors
- Author Affiliations
- Full Text
- Abstract
- Keywords
- DOI
- ISBN
- eISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-20 of 492
Search Results for Food and Drug Administration
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Article
Life Cycle of Medical Product Rules Issued by the US Food and Drug Administration
Available to Purchase
J Health Polit Policy Law (2014) 39 (4): 751–780.
Published: 01 August 2014
...Thomas J. Hwang; Jerry Avorn; Aaron S. Kesselheim Abstract The US Food and Drug Administration (FDA) uses rulemaking as one of its primary tools to protect the public health and implement laws enacted by Congress and the president. Because of the many effects that these rules have on social welfare...
FIGURES
View articletitled, Life Cycle of Medical Product Rules Issued by the US <span class="search-highlight">Food</span> and <span class="search-highlight">Drug</span> <span class="search-highlight">Administration</span>
View
PDF
for article titled, Life Cycle of Medical Product Rules Issued by the US <span class="search-highlight">Food</span> and <span class="search-highlight">Drug</span> <span class="search-highlight">Administration</span>
Journal Article
Managing Delegation in the Fda: Reducing Delay in New-Drug Review
Available to Purchase
J Health Polit Policy Law (2004) 29 (3): 397–430.
Published: 01 June 2004
...Mary K. Olson This article examines the effects of the user fee reform on the speed of drug review in the U.S. Food and Drug Administration. The results show that even after controlling for increased agency resources, the reform reduced review times among new-drug approvals by 34 percent (95...
Journal Article
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 649–672.
Published: 01 December 2022
... of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review .” JAMA Oncology 4 , no. 6 : 849 – 56 . https://doi.org/10.1001/jamaoncol.2017.5618 . Chen Emerson Y. , Haslam Alyson , and Prasad Vinay . 2020 . “ FDA...
FIGURES
View articletitled, Trends in the Quality of Evidence Supporting FDA <span class="search-highlight">Drug</span> Approvals: Results from a Literature Review
View
PDF
for article titled, Trends in the Quality of Evidence Supporting FDA <span class="search-highlight">Drug</span> Approvals: Results from a Literature Review
Includes: Supplementary data
Journal Article
The New NIH and FDA Medical Research Policies: Targeting Gender, Promoting Justice
Available to Purchase
J Health Polit Policy Law (1999) 24 (3): 531–565.
Published: 01 June 1999
...Karen L. Baird The National Institutes of Health (NIH) and Food and Drug Administration (FDA) have both recently revised their policies regarding the inclusion of women in clinical trials. Pressured by women's health activists and members of Congress, the NIH has vastly improved its policies...
Journal Article
Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits
Available to Purchase
J Health Polit Policy Law (2022) 47 (6): 673–690.
Published: 01 December 2022
...Rachel E. Sachs; Shelley A. Jazowski; Kyle A. Gavulic; Julie M. Donohue; Stacie B. Dusetzina Abstract Many state Medicaid officials are concerned about rising prescription drug spending, particularly drugs approved through the Food and Drug Administration's (FDA) accelerated approval pathway...
FIGURES
View articletitled, Medicaid and Accelerated Approval: Spending on <span class="search-highlight">Drugs</span> with and without Proven Clinical Benefits
View
PDF
for article titled, Medicaid and Accelerated Approval: Spending on <span class="search-highlight">Drugs</span> with and without Proven Clinical Benefits
Includes: Supplementary data
Journal Article
Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia : An Analysis of Litigated Cases
Available to Purchase
J Health Polit Policy Law (2021) 46 (3): 487–504.
Published: 01 June 2021
...Sheng Liu; Michelle M. Mello; Aaron S. Kesselheim Abstract Context: Food and Drug Administration (FDA) rules restrict pharmaceutical manufacturers from promoting drugs for non-FDA-approved (off-label) indications. When manufacturers violate this rule, it has in many cases led to unsafe prescribing...
FIGURES
View articletitled, Prospects for Enforcing Prohibitions on Off-Label <span class="search-highlight">Drug</span> Promotion after United States v. Caronia : An Analysis of Litigated Cases
View
PDF
for article titled, Prospects for Enforcing Prohibitions on Off-Label <span class="search-highlight">Drug</span> Promotion after United States v. Caronia : An Analysis of Litigated Cases
Includes: Supplementary data
Journal Article
Laetrile and the Fda: A Case of Reverse Regulation
Available to Purchase
J Health Polit Policy Law (1978) 3 (2): 181–195.
Published: 01 April 1978
... role of the Food and Drug Administration. Copyright © 1978 by the Department of Health Administration, Duke University Press 1978 Laetrile and the FDA: A Case of Reverse
Regulation
John F. Cannizzaro, and Madelon M Rosenfeld, Capital
University Law School...
Journal Article
Evidence and Access to Biomedical Interventions: The Case of Stem Cell Treatments
Available to Purchase
J Health Polit Policy Law (2016) 41 (5): 917–937.
Published: 01 October 2016
... should define and assess safety and effectiveness, and how? In the first section of the paper we describe the types of stem cells that may be therapeutically effective. We then describe how the US Food and Drug Administration asserted regulatory authority over certain stem cell interventions...
Journal Article
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization Process
Available to Purchase
J Health Polit Policy Law (2023) 48 (5): 799–820.
Published: 01 October 2023
...Neeraj G. Patel; Aaron S. Kesselheim; Jonathan J. Darrow Abstract Since 2004, the US Food and Drug Administration (FDA) has had the authority to allow access to unapproved medical products via the Emergency Use Authorization (EUA) pathway during times of emergency. It was rarely used until...
Journal Article
History and Politics of Medication Abortion in the United States and the Rise of Telemedicine and Self-Managed Abortion
Available to Purchase
J Health Polit Policy Law (2023) 48 (4): 485–510.
Published: 01 August 2023
...Carrie N. Baker Abstract This article examines the decades-long campaign to increase access to abortion pills in the United States, including advocates' work to win US Food and Drug Administration approval of mifepristone and misoprostol for abortion, the continuing restrictions on mifepristone...
FIGURES
Journal Article
Evidentiary Support in Public Comments to the FDA's Center for Tobacco Products
Available to Purchase
J Health Polit Policy Law (2017) 42 (4): 645–666.
Published: 01 August 2017
...Natalie Hemmerich; Elizabeth G. Klein; Micah Berman Abstract Electronic Nicotine Delivery Systems (ENDS) were introduced into the US market in 2007, and until recently these devices were unregulated at the federal level. In 2014, the US Food and Drug Administration (FDA) published a Notice...
Journal Article
J Health Polit Policy Law (2025) 50 (3): 397–437.
Published: 01 June 2025
... COVID-19 vaccines. Findings: Vaccine hesitancy spiked in the United States from late August to early October 2020. The authors identify several plausible triggers for this spike, all pertaining to the Food and Drug Administration and electoral politics. Heightened vaccine hesitancy occurred among...
FIGURES
| View All (7)
View articletitled, Does Policy Uncertainty Boost Vaccine Hesitancy? Political Controversy, the FDA, and COVID-19 Vaccine Hesitancy in Fall 2020
View
PDF
for article titled, Does Policy Uncertainty Boost Vaccine Hesitancy? Political Controversy, the FDA, and COVID-19 Vaccine Hesitancy in Fall 2020
Includes: Supplementary data
Journal Article
Coexistence, Conflict, and Cooperation: Public Policies toward Medical Devices
Available to Purchase
J Health Polit Policy Law (1986) 11 (3): 501–523.
Published: 01 June 1986
... the Medical Device Amend-
ments of 1976 was to authorize the Food and Drug Administration (FDA) to
ensure medical product safety. * The government also promotes innovation, pri-
marily through support for basic and applied research.' Congress expanded public
access for millions of elderly citizens...
Journal Article
Maximum Allowable Cost: Can the Government Control Drug Costs? A Retrospective Political Analysis of Events and Issues
Available to Purchase
J Health Polit Policy Law (1979) 4 (2): 155–175.
Published: 01 April 1979
..., Bethesda, Maryland; Dr. Mark Novitch, Associate Commissioner, Food and Drug Administration., Rockville, Maryland; Dr. James Russo, Vice President for Public Relations, Pharmaceutical Manufacturers Association, Washington, DC. Maximum Allowable Cost: Can the
Government Control Drug Costs...
View articletitled, Maximum Allowable Cost: Can the Government Control <span class="search-highlight">Drug</span> Costs? A Retrospective Political Analysis of Events and Issues
View
PDF
for article titled, Maximum Allowable Cost: Can the Government Control <span class="search-highlight">Drug</span> Costs? A Retrospective Political Analysis of Events and Issues
Journal Article
Staff Resources Speed FDA Drug Review: A Critical Analysis of the Returns to Resources in Approval Regulation
Available to Purchase
J Health Polit Policy Law (2004) 29 (3): 431–442.
Published: 01 June 2004
.... Food and Drug Administration. 2002 . Improving Public Health through Human Drugs: CDER Report to the Nation 2002 . Rockville, MD: U.S. Food and Drug Administration. Available online at www.fda.gov/cder/reports/rtn/2002/Rtn2002.PDF . Hilts, Philip. 2003 . Protecting American's Health: The FDA...
View articletitled, Staff Resources Speed FDA <span class="search-highlight">Drug</span> Review: A Critical Analysis of the Returns to Resources in Approval Regulation
View
PDF
for article titled, Staff Resources Speed FDA <span class="search-highlight">Drug</span> Review: A Critical Analysis of the Returns to Resources in Approval Regulation
Journal Article
Substantial Equivalence Standards in Tobacco Governance: Statutory Clarity and Regulatory Precedent for the FSPTCA
Available to Purchase
J Health Polit Policy Law (2017) 42 (4): 607–644.
Published: 01 August 2017
... Protection and Affordable Care Act of 2010 has received far more public attention, the FSPTCA (21 U.S.C. § 301 [2009]) creates a vast system of federal registration, reporting, and regulation of tobacco products. The Food and Drug Administration (FDA) now assumes the position of gatekeeper to the tobacco...
FIGURES
Journal Article
The Role of Courts in Shaping Health Equity
Open Access
J Health Polit Policy Law (2017) 42 (5): 749–770.
Published: 01 October 2017
... with its 2006 decision in Abigail Alliance v. Eschenbach (445 F.3d 470 [D.C. Cir. 2006]), holding that the Food and Drug Administration (FDA) must make experimental drugs more readily available to terminally ill patients for whom there are no other therapeutic options. Two of the three judges reasoned...
Journal Article
Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
Available to Purchase
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
...
to the participation of private interests in policy making (Alford 1975; Brickman, Jasanoff, and
Ilgen 1985).
618 Journal of Health Politics, Policy and Law
has led the Food and Drug Administration (FDA) to largely exclude indus-
try in policy development, which occurs indirectly through judicial appeal...
View articletitled, Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
View
PDF
for article titled, Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
Journal Article
The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
Available to Purchase
J Health Polit Policy Law (2013) 38 (3): 505–544.
Published: 01 June 2013
... of Health Politics, Policy and Law 2 , no. 1 : 32 – 47 . Strasburger Victor C. 2004 . “Children, Adolescents, and the Media.” Current Problems in Pediatric and Adolescent Health Care 34 , no. 2 : 54 – 113 . US Food and Drug Administration . 2005 . “FDA Updates Labeling...
View articletitled, The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
View
PDF
for article titled, The Politics and Strategy of Industry Self-Regulation: The Pharmaceutical Industry's Principles for Ethical Direct-to-Consumer Advertising as a Deceptive Blocking Strategy
Journal Article
The Rhetorical Transformations and Policy Failures of Prescription Drug Pricing Reform under the Trump Administration
Available to Purchase
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
... Lev . 2021 . “ States Still Can't Import Drugs from Canada. Now, Many Are Seeking to Import Canadian Prices .” Stat , February 18 . www.statnews.com/2021/02/18/states-canada-drug-prices/ . FDA (Food and Drug Administration) . 2019 . “ Importation of Prescription Drugs .” www.fda.gov...
View articletitled, The Rhetorical Transformations and Policy Failures of Prescription <span class="search-highlight">Drug</span> Pricing Reform under the Trump <span class="search-highlight">Administration</span>
View
PDF
for article titled, The Rhetorical Transformations and Policy Failures of Prescription <span class="search-highlight">Drug</span> Pricing Reform under the Trump <span class="search-highlight">Administration</span>
1